- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Abbott India Hit With Rs 2.40 Cr GST Penalty Over Alleged ITC Disallowance, Plans Appeal

New Delhi: Abbott India Limited has received an order imposing a GST penalty of Rs 2,40,46,491 from the Office of the Principal Commissioner of CGST & Central Excise, Mumbai East Commissionerate.
The order was received on December 30, 2025, and relates to the financial years 2018–19, 2019–20, 2021–22, and 2023–24. The penalty has been levied on account of the disallowance of Input Tax Credit (ITC) by the GST authorities.
The company made the disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as part of its statutory obligation to inform investors about material regulatory developments. Abbott India clarified that the action has been initiated by the GST tax authorities following assessment proceedings conducted by the jurisdictional office in Mumbai East.
According to the details shared by the company, the order alleges violations linked to the availment of input tax credit. However, Abbott India has stated that it does not agree with the findings of the tax authorities and believes that the demand raised through the order is not maintainable under law. The company has also emphasized that the penalty does not have any material impact on its financial position, business operations, or other corporate activities.
Abbott India further informed that it is in the process of preferring an appeal against the said order before the appropriate appellate authority. The company expressed confidence in its legal position and expects to receive relief through the appellate process.
The disclosure was submitted to BSE Limited, and has been duly signed by Sangeeta Shetty, Company Secretary, on behalf of Abbott India Limited. The company reiterated its commitment to regulatory compliance and stated that it will continue to take all necessary steps to protect its interests while following due legal process.
Abbott India Limited, which is headquartered at Godrej BKC, Bandra-Kurla Complex, Mumbai, has assured stakeholders that the development will not adversely affect its ongoing operations or financial stability.
M. Pharm (Pharmaceutics)
Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

